Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice-Reference-Cited by-同舟云学术

Nitro-fatty acids protect against steatosis and fibrosis during development of nonalcoholic fatty liver disease in mice

Published:2019-03 Issue: Volume:41 Page:62-72
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Rom Oren,Xu Guan,Guo Yanhong^ORCID,Zhu Yunhao,Wang Huilun,Zhang Jifeng^ORCID,Fan Yanbo,Liang Wenying,Lu Haocheng^ORCID,Liu Yuhao,Aviram Michael,Liu Zhipeng,Kim Seongho,Liu Wanqing,Wang Xueding,Chen Y. Eugene,Villacorta Luis^ORCID

Funder

NIH

American Heart Association

Michigan-Israel Partnership Research

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference42 articles.

1. Pathophysiology and mechanisms of nonalcoholic fatty liver disease;Haas;Annu Rev Physiol,2016

2. Human fatty liver disease: old questions and new insights;Cohen;Science,2011

3. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2018

4. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

5. Management of NAFLD: a stage-based approach;Rinella;Nat Rev Gastroenterol Hepatol,2016

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Indigenous wisdom of a Kwatha to treat NASH: An insight into the mechanism;Journal of Ethnopharmacology;2024-05

2. Nitro-fatty acids: mechanisms of action, roles in metabolic diseases, and therapeutics;Current Medicine;2024-03-07

3. Farnesoid X receptor overexpression prevents hepatic steatosis through inhibiting AIM2 inflammasome activation in nonalcoholic fatty liver disease;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-02

4. Integrated transcriptomic landscape of the effect of anti‐steatotic treatments in high‐fat diet mouse models of non‐alcoholic fatty liver disease;The Journal of Pathology;2024-01-05

5. Fatty acid nitroalkenes – Multi-target agents for the treatment of sickle cell disease;Redox Biology;2023-12